152 related articles for article (PubMed ID: 30445030)
1. Development of up-converting phosphor technology-based lateral flow assay for quantitative detection of serum PIVKA-II: Inception of a near-patient PIVKA-II detection tool.
Huang Y; Zhang S; Zheng Q; Li Y; Yu L; Wu Q; Zheng J; Wu Y; Qiu F; Gao Q; Zhang J
Clin Chim Acta; 2019 Jan; 488():202-208. PubMed ID: 30445030
[TBL] [Abstract][Full Text] [Related]
2. A quantitative analytical method for PIVKA-II using multiple reaction monitoring-mass spectrometry for early diagnosis of hepatocellular carcinoma.
Sohn A; Kim H; Yu SJ; Yoon JH; Kim Y
Anal Bioanal Chem; 2017 Apr; 409(11):2829-2838. PubMed ID: 28168546
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
[TBL] [Abstract][Full Text] [Related]
4. Fully validated SRM-MS-based method for absolute quantification of PIVKA-II in human serum: Clinical applications for patients with HCC.
Sohn A; Kim H; Yeo I; Kim Y; Son M; Yu SJ; Yoon JH; Kim Y
J Pharm Biomed Anal; 2018 Jul; 156():142-146. PubMed ID: 29702392
[TBL] [Abstract][Full Text] [Related]
5. Development and evaluation of analytical performance of a fully automated chemiluminescent immunoassay for protein induced by vitamin K absence or antagonist II.
Fujita K; Kinukawa H; Ohno K; Ito Y; Saegusa H; Yoshimura T
Clin Biochem; 2015 Dec; 48(18):1330-6. PubMed ID: 26210849
[TBL] [Abstract][Full Text] [Related]
6. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
[TBL] [Abstract][Full Text] [Related]
7. A comparative evaluation of Golgi protein-73, fucosylated hemopexin, α-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
Morota K; Nakagawa M; Sekiya R; Hemken PM; Sokoll LJ; Elliott D; Chan DW; Dowell BL
Clin Chem Lab Med; 2011 Apr; 49(4):711-8. PubMed ID: 21231906
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of AFP, PIVKA-II, and Their Combination in Diagnosing Hepatocellular Carcinoma Based on Upconversion Luminescence Immunochromatography.
Zhang SG; Huang Y
Lab Med; 2022 Sep; 53(5):488-494. PubMed ID: 35551399
[TBL] [Abstract][Full Text] [Related]
9. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
[TBL] [Abstract][Full Text] [Related]
10. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
Yoon YJ; Han KH; Kim DY
Scand J Gastroenterol; 2009; 44(7):861-6. PubMed ID: 19391065
[TBL] [Abstract][Full Text] [Related]
11. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis.
Caviglia GP; Ribaldone DG; Abate ML; Ciancio A; Pellicano R; Smedile A; Saracco GM
Scand J Gastroenterol; 2018 Jun; 53(6):734-740. PubMed ID: 29667463
[TBL] [Abstract][Full Text] [Related]
12. [The value of serum abnormal prothrombin in clinical application of hepatocellular carcinoma].
Zhang JW; Guan LY; E CY; Yang JH; Xuan W; Meng ZH; Li W
Zhonghua Wai Ke Za Zhi; 2020 Oct; 58(10):776-781. PubMed ID: 32993265
[No Abstract] [Full Text] [Related]
13. Analytical and Clinical Performance Evaluation of the Abbott Architect PIVKA Assay.
Ko DH; Hyun J; Kim HS; Park MJ; Kim JS; Park JY; Shin DH; Cho HC
Ann Clin Lab Sci; 2018 Jan; 48(1):75-80. PubMed ID: 29531000
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.
Seo SI; Kim HS; Kim WJ; Shin WG; Kim DJ; Kim KH; Jang MK; Lee JH; Kim JS; Kim HY; Kim DJ; Lee MS; Park CK
World J Gastroenterol; 2015 Apr; 21(13):3928-35. PubMed ID: 25852278
[TBL] [Abstract][Full Text] [Related]
15. The influence of alcoholic liver disease on serum PIVKA-II levels in patients without hepatocellular carcinoma.
Kang KH; Kim JH; Kang SH; Lee BJ; Seo YS; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
Gut Liver; 2015 Mar; 9(2):224-30. PubMed ID: 25473073
[TBL] [Abstract][Full Text] [Related]
16. Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.
Poté N; Cauchy F; Albuquerque M; Voitot H; Belghiti J; Castera L; Puy H; Bedossa P; Paradis V
J Hepatol; 2015 Apr; 62(4):848-54. PubMed ID: 25450201
[TBL] [Abstract][Full Text] [Related]
17. Development and Evaluation of Up-Converting Phosphor Technology-Based Lateral Flow Assay for Quantitative Detection of NT-proBNP in Blood.
Yang X; Liu L; Hao Q; Zou D; Zhang X; Zhang L; Li H; Qiao Y; Zhao H; Zhou L
PLoS One; 2017; 12(2):e0171376. PubMed ID: 28151978
[TBL] [Abstract][Full Text] [Related]
18. Epitope characterization of an anti-PIVKA-II antibody and evaluation of a fully automated chemiluminescent immunoassay for PIVKA-II.
Kinukawa H; Shirakawa T; Yoshimura T
Clin Biochem; 2015 Nov; 48(16-17):1120-5. PubMed ID: 26297114
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of PIVKA-II After Living-donor Liver Transplantation for Hepatocellular Carcinoma.
Park MS; Lee KW; Kim H; Choi YR; Hong G; Yi NJ; Suh KS
Transplant Proc; 2017 Jun; 49(5):1109-1113. PubMed ID: 28583537
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]